Therapeutic Strategies for Ovarian Cancer in Point of HGF/c-MET Targeting

被引：5
作者：
Kim, Hyun Jung [1 ,2 ,3 ]
机构：
[1] Kookmin Univ, Dept Biopharmaceut Chem, Seoul 02707, South Korea
[2] Kookmin Univ, Sch Appl Chem, Seoul 02707, South Korea
[3] Kookmin Univ, Antibody Res Inst, Seoul 02707, South Korea
来源：
MEDICINA-LITHUANIA | 2022年 / 58卷 / 05期
基金：
新加坡国家研究基金会;
关键词：
hepatocyte growth factor; c-MET; ovarian cancer; humanized monoclonal antibody; anti-cancer; therapeutics; HEPATOCYTE GROWTH-FACTOR; RECURRENT EPITHELIAL OVARIAN; RECEPTOR TYROSINE KINASE; PHASE-II EVALUATION; C-MET; SCATTER FACTOR; FALLOPIAN-TUBE; MESENCHYMAL TRANSITION; FACTOR/SCATTER FACTOR; CLINICAL-SIGNIFICANCE;
D O I：
10.3390/medicina58050649
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Ovarian cancer is the fifth leading cause of cancer deaths in women and is regarded as one of the most difficult cancers to treat. Currently, studies are being conducted to develop therapeutic agents for effective treatment of ovarian cancer. In this review, we explain the properties of the hepatocyte growth factor (HGF)/mesenchymal-epithelial transition factor (c-MET) and how the signaling pathway of HGF/c-MET is activated in different cancers and involved in tumorigenesis and metastasis of ovarian cancer. We present the findings of clinical studies using small chemicals or antibodies targeting HGF/c-MET signaling in various cancer types, particularly in ovarian cancer. We also discuss that HGF/c-MET-targeted therapy, when combined with chemo drugs, could be an effective strategy for ovarian cancer therapeutics.
引用
收藏
页数：12
相关论文
共 108 条
  • [1] Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers
    Adjei, Alex A.
    Schwartz, Brian
    Garmey, Edward
    [J]. ONCOLOGIST, 2011, 16 (06) : 788 - 799
  • [2] Ovarian surface epithelium: Biology, endocrinology, and pathology
    Auersperg, N
    Wong, AST
    Choi, KC
    Kang, SK
    Leung, PCK
    [J]. ENDOCRINE REVIEWS, 2001, 22 (02) : 255 - 288
  • [3] The role of HGF/c-MET signaling pathway in lymphoma
    Bao Quoc Lam
    Dai, Lu
    Qin, Zhiqiang
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9 : 1 - 8
  • [4] A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of met
    Basilico, Cristina
    Arnesano, Addolorata
    Galluzzo, Maria
    Comoglio, Paolo M.
    Michieli, Paolo
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2008, 283 (30) : 21267 - 21277
  • [5] Overexpression of the c-Met/HGF receptor and its prognostic significance in uterine cervix carcinomas
    Baykal, C
    Ayhan, A
    Al, A
    Yüce, K
    Ayhan, A
    [J]. GYNECOLOGIC ONCOLOGY, 2003, 88 (02) : 123 - 129
  • [6] RETRACTED: Epigenetic regulation of HGF/Met receptor axis is critical for the outgrowth of bone metastasis from breast carcinoma (Retracted article. See vol. 13, 2022)
    Bendinelli, Paola
    Maroni, Paola
    Matteucci, Emanuela
    Desiderio, Maria Alfonsina
    [J]. CELL DEATH & DISEASE, 2017, 8 : e2578 - e2578
  • [7] Microtubule-targeted anticancer agents and apoptosis
    Bhalla, KN
    [J]. ONCOGENE, 2003, 22 (56) : 9075 - 9086
  • [8] Met, metastasis, motility and more
    Birchmeier, C
    Birchmeier, W
    Gherardi, E
    Vande Woude, GF
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2003, 4 (12) : 915 - 925
  • [9] Blagosklonny MV, 1996, CANCER RES, V56, P1851
  • [10] IDENTIFICATION OF THE HEPATOCYTE GROWTH-FACTOR RECEPTOR AS THE C-MET PROTOONCOGENE PRODUCT
    BOTTARO, DP
    RUBIN, JS
    FALETTO, DL
    CHAN, AML
    KMIECIK, TE
    VANDEWOUDE, GF
    AARONSON, SA
    [J]. SCIENCE, 1991, 251 (4995) : 802 - 804
12345678910